## **Other relevant codes** Other relevant HCPCS codes related to HCPCS Q5123 (Injection, rituximab-arrx, biosimilar, Riabni 10 mg) include codes for other rituximab biosimilars and related biologic drugs: - Q5115: Injection, rituximab-abbs, biosimilar, 10 mg (Truxima) - Q5119: Injection, rituximab-pvvr, biosimilar, 10 mg (Ruxience) - J9312: Injection, rituximab, 10 mg (reference rituximab drug) - J9311: Injection, rituximab 10 mg and hyaluronidase (combination product) - J3590: Unclassified biologics (used sometimes for unspecified biologics) - Q5122: Injection, pegfilgrastim-apgf, biosimilar, 0.5 mg - Q5124: Injection, ranibizumab-nuna, biosimilar, 0.1 mg Frequently asked questions
[11] Long-term metformin therapy reduces calcium-dependent intrinsic-factor binding, lowering B12 absorption and potentially necessitating higher or more frequent parenteral doses
Frequency: Can be weekly, monthly, or quarterly, depending on individual needs
It is pseudoscientific nonsense of the first order
A successful result for this procedure is typically evaluated at a 30-50% decrease in total migraines